Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement

Shattuck Labs, Inc.

First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.
Closed private placement of up to $103M in August 2025; cash expected to fund operations into 2029.
Net loss of $10.1M ($0.14 per share) vs $16.6M ($0.33) in Q3 2024; R&D expenses down to $7.6M.
Cash and investments at $86.1M as of Sep 30, 2025, supporting pipeline advancement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.